| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EW | Common Stock | Award | $0 | +3.78K | +13.69% | $0.00 | 31.3K | May 3, 2022 | Direct | F1 |
| transaction | EW | Common Stock | Options Exercise | $509K | +23.4K | +74.66% | $21.76 | 54.7K | May 4, 2022 | Direct | F2 |
| transaction | EW | Common Stock | Tax liability | -$52.2K | -493 | -0.9% | $105.93 | 54.3K | May 4, 2022 | Direct | |
| transaction | EW | Common Stock | Sale | -$402K | -3.8K | -7% | $105.88 | 50.5K | May 4, 2022 | Direct | F2, F3 |
| transaction | EW | Common Stock | Sale | -$954K | -9.16K | -18.15% | $104.18 | 41.3K | May 4, 2022 | Direct | F2, F4 |
| transaction | EW | Common Stock | Sale | -$1.1M | -10.4K | -25.3% | $105.10 | 30.9K | May 4, 2022 | Direct | F2, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EW | Employee Stock Option (Right to Acquire) | Award | $0 | +30.6K | $0.00 | 30.6K | May 3, 2022 | Common Stock | 30.6K | $105.93 | Direct | F6 | |
| transaction | EW | Performance Rights | Award | $0 | +4.73K | $0.00 | 4.73K | May 3, 2022 | Common Stock | 4.73K | Direct | F7 | ||
| transaction | EW | Employee Stock Option (Right to Acquire) | Options Exercise | $0 | -23.4K | -100% | $0.00* | 0 | May 4, 2022 | Common Stock | 23.4K | $21.76 | Direct |
| Id | Content |
|---|---|
| F1 | These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
| F2 | The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021. |
| F3 | This transaction was executed in multiple trades at prices ranging from $105.77 to $105.92. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| F4 | This transaction was executed in multiple trades at prices ranging from $103.77 to $104.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| F5 | This transaction was executed in multiple trades at prices ranging from $104.77 to $105.74. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| F6 | These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
| F7 | Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. |
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.